finance.yahoo.com ·
Gilead Sciences Q1 Earnings Call
Topic context
This topic has been covered 393273 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedGilead Sciences reported strong Q1 2026 earnings driven by HIV product growth. The company raised full-year guidance and has upcoming FDA priority review for BIC/LEN. Commercial mechanism is moderate: revenue and margin expansion from HIV franchise, with pipeline catalyst. No supply chain or scarcity issues mentioned.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 total product sales $6.9B, +5% YoY
- HIV product sales $5.0B, +10% YoY
- BIKTARVY sales $3.4B
- DESCOVY sales $807M, +38% YoY
- Full-year guidance raised to $30.0-$30.4B
Gilead Sciences' BIKTARVY and DESCOVY face flat impact in the short-term due to modest earnings expectations; magnitude 1.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
fool.com
Canaan Can Q1 2026 Earnings Transcript
livemint.com